The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
It's unclear how possible alliances for other NFT categories, like video and fantasy sports, are doing.
The key selling point of this system is the ability to remotely manipulate digital avatars from a computer, camera, and microphone at home
LEGO reported strong sales growth driven by store openings and sales of Harry Potter and Star Wars sets.
The partnership will also include more focus on new sustainable technology solutions beyond the racetrack.
KT and AMC Networks collaborate for joint content production and distribution of shows, including 'The Walking Dead.'
MonkeyLeague will release a fresh set of AC Milan-themed game materials, including characters, skins, and venues.
Voyager Digital announces a successful bankruptcy auction of its assets with FTX US as the winning bidder.
With the integration of live streaming, the NBA app would offer a data-driven, tailored experience that collects team and league material.
Galena Biopharma to Present at NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference
SAN RAMON, Calif., Jan. 11, 2016 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference. The presentation will take place on Monday, January 18, 2015 at 2:30 p.m. ET in Sandpiper Bay, Florida.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancer and in a Phase 1b given sequentially with GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
SVP, Investor Relations & Corporate Communications
What is a semiconductor? An electrical engineer explains how these critical electronic components work and how they are made